All Stories

  1. Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
  2. Corticosteroids in COVID-19: one size does not fit all
  3. Identification and treatment of T2-low asthma in the era of biologics
  4. Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature
  5. Health care resource utilization (HCRU) in early and late diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients in UK primary care
  6. Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care
  7. Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment
  8. Late Breaking Abstract - Blood Eosinophils as Predictor of Outcomes in hospitalized COPD Exacerbations: Results from a Prospective Study
  9. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study
  10. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
  11. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study
  12. Correction
  13. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial
  14. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
  15. Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study
  16. COPD exacerbation rates with IND/GLY
  17. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
  18. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD
  19. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
  20. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
  21. The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease?
  22. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
  23. Editorial (Thematic Issue: Biomarkers in the Management of Chronic Lung Disease)
  24. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?